CSX CORPORATION $500,000,000 7.375% Notes Due 2019 UNDERWRITING AGREEMENT Dated: January 14, 2009
Exhibit 1.1
EXECUTION
VERSION
CSX
CORPORATION
$500,000,000
7.375% Notes Due 2019
Dated:
January 14, 2009
CSX
CORPORATION
$500,000,000
7.375% Notes Due 2019
January
14, 2009
Credit
Suisse Securities (USA) LLC
X.X.
Xxxxxx Securities Inc
UBS
Securities LLC
As
Representatives of the Underwriters
c/o
|
Credit
Suisse Securities (USA) LLC
Eleven
Madison Avenue
New
York, N.Y. 10010
|
X.X.
Xxxxxx Securities Inc.
000
Xxxx Xxxxxx
Xxx
Xxxx, X.X. 00000
|
|
UBS
Securities LLC
000
Xxxxxxxxxx Xxxx.
Xxxxxxxx,
XX 00000
|
Ladies
and Gentlemen:
CSX
CORPORATION, a Virginia corporation (the “Company”), proposes to issue and sell
to the parties named in Schedule II hereto (the “Underwriters”), for whom you are
acting as representatives (the “Representatives”), $500,000,000
principal amount of its 7.375% Notes due 2019 (the “Notes”). The Notes are to be issued
under an indenture (the “Indenture”) dated as of August 1,
1990, between the Company and The Bank of New York Mellon Trust Company, N.A.
(formerly known as The Bank of New York Trust Company, N.A.), successor to
JPMorgan Chase Bank, N.A., (formerly The Chase Manhattan Bank), as trustee (the
“Trustee”), as supplemented and
amended by the First Supplemental Indenture dated as of June 15, 1991, the
Second Supplemental Indenture dated as of May 6, 1997, the Third Supplemental
Indenture dated as of April 22, 1998, the Fourth Supplemental Indenture dated as
of October 30, 2001, the Fifth Supplemental Indenture dated as of October 27,
2003, the Sixth Supplemental Indenture dated as of September 23, 2004 and the
Seventh Supplemental Indenture dated as of April 25, 2007.
1
In
connection with the sale of the Notes, the Company has prepared and filed with
the Securities and Exchange Commission (the “Commission”) a registration statement
on Form S-3ASR (Registration No. 333-140732) for the registration of debt
securities, including the Notes, trust preferred securities (and related
guarantee and agreement as to expenses and liabilities), common stock, preferred
stock, depositary shares and securities warrants, under the Securities Act of
1933, as amended (the “Securities
Act”). On December 10, 2007, the Company and CSX Transportation, Inc., a
Virginia corporation, filed with the Commission Post-Effective Amendment No. 1
to the Registration Statement, including the related Base Prospectus, which
Post-Effective Amendment No. 1 became effective upon filing under Rule 462(e)
and 462(f) under the Securities Act. Such amended Registration Statement covers
the registration of the Notes under the Securities Act. Any reference herein to
the Registration Statement, the Base Prospectus, any Preliminary Prospectus or
the Final Prospectus shall be deemed to refer to and include the documents
incorporated by reference therein pursuant to Item 12 of Form S-3 which were
filed under the Exchange Act on or before the Effective Date of the Registration
Statement or the issue date of the Base Prospectus, any Preliminary Prospectus
or the Final Prospectus, as the case may be; and any reference herein to the
terms “amend,” “amendment” or “supplement” with respect to the Registration
Statement, the Base Prospectus, any Preliminary Prospectus or the Final
Prospectus shall be deemed to refer to and include the filing of any document
under the Exchange Act (as defined in Section 1(b) hereof) after the Effective
Date of the Registration Statement or the issue date of the Base Prospectus, any
Preliminary Prospectus or the Final Prospectus, as the case may be, deemed to be
incorporated therein by reference. The Company hereby confirms that it has
authorized the use of the Base Prospectus, any Preliminary Prospectus and the
Final Prospectus, and any amendment or supplement thereto, in connection with
the offer and sale of the Notes by the Underwriters. Certain terms used herein
are defined in Section 18 hereof.
1. Representations and
Warranties. The Company represents and warrants to, and agrees with, each
Underwriter as set forth below in this Section 1. Any reference to persons
acting on behalf of the Company does not include any of the Underwriters, with
respect to whom the Company makes no representation.
(a) The
Company meets the requirements for use of Form S-3ASR under the Securities Act
and has prepared and filed with the Commission an automatic shelf registration
statement as defined in Rule 405, on Form S-3ASR, including a related Base
Prospectus, for registration under the Securities Act of the offering and sale
of the Notes. Such Registration Statement, including any amendments thereto
filed prior to the Applicable Time, has become effective. The Company may have
filed with the Commission, as part of an amendment to the Registration Statement
or pursuant to Rule 424(b), one or more preliminary prospectus supplements
relating to the Notes, each of which has previously been electronically
furnished to you. The Company will file with the Commission a final prospectus
supplement relating to the Notes in accordance with Rule 424(b). As filed, such
final prospectus supplement shall contain all information required by the
Securities Act and the rules thereunder, and, except to the extent the
Representatives shall agree in writing to a modification, shall be in all
substantive respects in the form furnished to you prior to the Applicable Time
or, to the extent not completed at the Applicable Time, shall contain only such
specific additional information and other changes (beyond that contained in the
Base Prospectus and any Preliminary Prospectus) as the Company has advised you,
prior to the Applicable Time, will be included or made therein. The Registration
Statement, at the Applicable Time, meets the requirements set forth in Rule
415(a)(1)(x).
2
(b) On the
Effective Date, the Registration Statement did, and the Final Prospectus (and
any supplement thereto), as of its date and on the Closing Date (as defined in
Section 3 hereof), will, comply in all material respects with the requirements
of the Securities Act and the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)
and the Trust Indenture Act of 1939, as amended (the “TIA”), and the rules and regulations
of the Commission promulgated thereunder. On the Effective Date, the
Registration Statement did not, and will not, contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading. On the Effective Date
and on the Closing Date, the Indenture did or will comply in all material
respects with the applicable requirements of the TIA and the rules thereunder.
On the date of any filing pursuant to Rule 424(b) and on the Closing Date, the
Final Prospectus (together with any supplement thereto) will not include any
untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; provided, however, that the Company makes no representations or
warranties as to (i) that part of the Registration Statement which shall
constitute the Statement of Eligibility and Qualification (Form T-1) under the
TIA of the Trustee or (ii) the information contained in or omitted from the
Registration Statement or the Final Prospectus (or any supplement thereto) in
reliance upon and in conformity with information furnished in writing to the
Company by or on behalf of any Underwriter through the Representatives
specifically for inclusion in the Registration Statement or the Final Prospectus
(or any supplement thereto), it being understood and agreed that the only such
information furnished by or on behalf of any Underwriters consists of the
information described as such in Section 7 hereof.
(c) As of the
Applicable Time, (i) the Disclosure Package and (ii) each electronic roadshow
when taken together as a whole with the Disclosure Package, do not contain any
untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The preceding sentence does not apply to
statements in or omissions from the Disclosure Package based upon and in
conformity with written information furnished to the Company by any Underwriter
through the Representatives specifically for use therein, it being understood
and agreed that the only such information furnished by or on behalf of any
Underwriter consists of the information described as such in Section 7
hereof.
(d) (i) At
the time of filing the Registration Statement, (ii) at the time of the most
recent amendment thereto for the purposes of complying with Section 10(a)(3) of
the Securities Act (whether such amendment was by post-effective amendment,
incorporated report filed pursuant to Sections 13 or 15(d) of the Exchange Act
or form of prospectus), (iii) at the time the Company or any person acting on
its behalf (within the meaning, for this clause only, of Rule 163(c)) made any
offer relating to the Notes in reliance on the exemption in Rule 163, and (iv)
at the Applicable Time (with such date being used as the determination date for
purposes of this clause (iv)), the Company was or is (as the case may be) a
“well-known seasoned issuer” as defined in Rule 405. The Company agrees to pay
the fees required by the Commission relating to the Notes within the time
required by Rule 456(b)(1) without regard to the proviso therein and otherwise
in accordance with Rules 456(b) and 457(r).
3
(e) (i) At
the earliest time after the filing of the Registration Statement that the
Company or another offering participant made a bona fide offer (within the
meaning of Rule 164(h)(2)) of the Notes and (ii) as of the Applicable Time (with
such date being used as the determination date for purposes of this clause
(ii)), the Company was not and is not an Ineligible Issuer (as defined in Rule
405), without taking account of any determination by the Commission pursuant to
Rule 405 that it is not necessary that the Company be considered an Ineligible
Issuer.
(f) Each
Issuer Free Writing Prospectus and the final term sheet prepared and filed
pursuant to Section 4(I)(c) hereto does not include any information that
conflicts with the information contained in the Registration Statement,
including any document incorporated therein and any prospectus supplement deemed
to be a part thereof that has not been superseded or modified. The foregoing
sentence does not apply to statements in or omissions from any Issuer Free
Writing Prospectus based upon and in conformity with written information
furnished to the Company by any Underwriter through the Representatives
specifically for use therein, it being understood and agreed that the only such
information furnished by or on behalf of any Underwriter consists of the
information described as such in Section 7 hereof.
(g) Since the
respective dates as of which information is given in the Registration Statement,
the Disclosure Package and the Final Prospectus, except as may otherwise be
stated therein or contemplated thereby, there has been no material adverse
change in the condition, financial or otherwise, or in the earnings, business or
properties of the Company and its subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business.
(h) The
Company has not taken and will not take, directly or indirectly, any action
designed to or which has constituted or which might reasonably be expected to
cause or result in stabilization or manipulation of the price of the Notes
(other than any stabilization done by the Underwriters, as to which the Company
makes no representation).
(i) The
Company is not an “investment company” within the meaning of the Investment
Company Act of 1940, as amended (the “Investment Company Act”),
without taking account of any exemption arising out of the number of holders of
the Company’s securities.
(j) The
information, if any, provided by the Company pursuant to Section 4(I)(g) hereof
will not, at the date thereof, contain any untrue statement of a material fact
or omit to state any material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not
misleading.
4
(k) This
Agreement has been duly authorized, executed and delivered by the
Company.
(l) The
Indenture has been duly authorized, executed and delivered by the Company; the
Indenture (assuming that the Indenture has been duly authorized, executed and
delivered by the Trustee) constitutes a valid and legally binding obligation of
the Company enforceable against the Company in accordance with its terms,
subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting
creditors’ rights and to general equity principles; the Notes have been duly
authorized, and when executed, issued and delivered by the Company and
authenticated in the manner provided in the Indenture, will constitute valid and
legally binding obligations of the Company enforceable against the Company in
accordance with their terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors’ rights and to general equity principles; and
the Notes conform to the description thereof contained in the Disclosure Package
and the Final Prospectus.
(m) No
consent, approval, authorization or order of, or filing with, any governmental
agency or body or any court is required for the consummation of the transactions
contemplated herein, except for a filing of any Preliminary Prospectus and the
Final Prospectus under Rule 424(b) of the Securities Act and such as may be
required under state securities laws.
(n) The
execution, delivery and performance of this Agreement and the issuance and sale
of the Notes and compliance with the terms and provisions thereof will not
result in a material breach or violation of any of the terms and provisions of,
or constitute a default under, any statute, rule, regulation or order of any
governmental agency or body or any court having jurisdiction over the Company or
any Significant Subsidiary (as defined below) of the Company or any of their
properties or any agreement or instrument to which the Company or any
Significant Subsidiary of the Company is a party or by which the Company or any
Significant Subsidiary of the Company is bound or to which any of the properties
of the Company or any Significant Subsidiary of the Company is subject, or the
charter, by-laws or operating agreement, as the case may be, of the Company or
any Significant Subsidiary of the Company.
2. Purchase and Sale.
Subject to the terms and conditions and in reliance upon the representations and
warranties herein set forth, the Company agrees to sell to each Underwriter, and
each Underwriter agrees, severally and not jointly, to purchase from the
Company, at a purchase price of 98.711% of the principal amount thereof, the
principal amount of the Notes, plus accrued interest, if any, from January 20,
2009, set forth opposite such Underwriter’s name in Schedule II
hereto.
3. Delivery and Payment.
Delivery of and payment for the Notes shall be made at 10:00 AM, New York City
time, on January 20, 2009, or such later date (not later than seven full
Business Days thereafter) as the Representatives shall designate, which date and
time may be postponed by agreement between the Representatives and the Company
or as provided in Section 8 hereof (such date and time of delivery and payment
being herein called the “Closing Date”).
Delivery of the Notes shall be made to the Representatives for the respective
accounts of the Underwriters against payment by the Underwriters through the
Representatives of the purchase price thereof to or upon the order of the
Company by wire transfer of Federal funds or other immediately available funds
or in such other manner of payment as may be agreed by the Company and the
Representatives.
5
Delivery
of any Notes to be issued in definitive certificated form shall be made on the
Closing Date at such location, and in such names and denominations, as the
Representatives shall designate at least one Business Day in advance of the
Closing Date. The Company agrees to have the Notes available for inspection,
checking and packaging by the Representatives in New York, New York, not later
than 1:00 PM on the Business Day prior to the Closing Date. The closing for the
purchase and sale of the Notes shall occur at the office of Shearman &
Sterling LLP, 000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000 (“Counsel for
the Underwriters”) or such other place as the parties hereto
shall agree.
The Notes
will be issued in the form of one fully registered global Note in the
denomination of $500,000,000 which will be deposited with, or in accordance with
the instructions of, The Depository Trust Company, New York, New York (“DTC”) and registered in the name of
DTC’s nominee. Except as provided in the Indenture, beneficial owners of the
Notes will not have the right to have the Notes registered in their names, will
not receive or be entitled to receive physical delivery of such Notes, and will
not be considered the owners or holders thereof under the
Indenture.
4. Agreements. (I)
The Company agrees with each Underwriter that:
(a) The
Company will furnish to each Underwriter and to Counsel for the Underwriters,
without charge, during the period referred to in paragraph (e) below, as many
copies of each of the Preliminary Prospectus, any Issuer Free Writing Prospectus
and any amendments and supplements thereto (to be delivered electronically) and
the Final Prospectus, as it may reasonably request. The Company will pay the
expenses of printing or other production of all documents relating to the
offering.
(b) Prior to
the termination of the offering of the Notes, the Company will not file any
amendment of the Registration Statement or supplement (including the Final
Prospectus or any Preliminary Prospectus) to the Base Prospectus unless the
Company has furnished you a copy for your review prior to filing and will not
file any such proposed amendment or supplement to which you reasonably object.
The Company will promptly advise the Representatives (i) when the Final
Prospectus, and any supplement thereto, shall have been filed (if required) with
the Commission pursuant to Rule 424(b), (ii) when, prior to termination of the
offering of the Notes, any amendment to the Registration Statement shall have
been filed or become effective, (iii) of any request by the Commission or its
staff for any amendment of the Registration Statement, or any Rule 462(b)
Registration Statement, or for any supplement to the Final Prospectus or for any
additional information, (iv) of the issuance by the Commission of any stop order
suspending the effectiveness of the Registration Statement or of any notice
objecting to its use or the institution or threatening of any proceeding for
that purpose and (v) of the receipt by the Company of any notification with
respect to the suspension of the qualification of the Notes for sale in any
jurisdiction or the institution or threatening of any proceeding for such
purpose. The Company will use its best efforts to prevent the issuance of any
such stop order or the occurrence of any such suspension or objection to the use
of the Registration Statement and, upon such issuance, occurrence or notice of
objection, to obtain as soon as possible the withdrawal of such stop order or
relief from such occurrence or objection, including, if necessary, by filing an
amendment to the Registration Statement or a new registration statement and
using its best efforts to have such amendment or new registration statement
declared effective as soon s practicable.
6
(c) To
prepare a final term sheet, in the form of Schedule I hereto, containing solely
a description of final terms of the Notes and the offering thereof, in a form
approved by you and to file such term sheet pursuant to Rule 433(d) within the
time required by such Rule.
(d) If, at
any time prior to the filing of the Final Prospectus pursuant to Rule 424(b),
any event occurs as a result of which the Disclosure Package would include any
untrue statement of a material fact or omit to state any material fact necessary
to make the statements therein in the light of circumstances under which they
were made at such time not misleading, the Company will (i) notify promptly the
Representatives so that any use of the Disclosure Package may cease until it is
amended or supplemented; (ii) amend or supplement the Disclosure Package to
correct such statement or omission; and (iii) supply any amendment or supplement
to you in such quantities as you may reasonably request.
(e) If at any
time prior to the earlier of (i) completion of the sale of the Notes by the
Underwriters (as determined by the Representatives) or (ii) six months from the
date hereof, any event occurs as a result of which the Final Prospectus, as then
amended or supplemented, would include any untrue statement of a material fact
or omit to state any material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading, or if
it should be necessary to amend or supplement the Final Prospectus (including
any document incorporated by reference therein which was filed under the
Exchange Act) to comply with the Exchange Act or the rules thereunder or other
applicable law, including in connection with the use or delivery of the Final
Prospectus, the Company will promptly notify the Representatives of the same
and, subject to the requirements of paragraph (b) of this Section 4, will
prepare and provide to the Representatives pursuant to paragraph (a) of this
Section 4 an amendment or supplement which will correct such statement or
omission or effect such compliance and, if such an amendment or supplement is
required to be filed under the Exchange Act and is to be incorporated by
reference in the Final Prospectus, will file such amendment or supplement with
the Commission. The Representatives will promptly advise the Company, in
writing, of the completion of the initial distribution of the
Notes.
(f) The
Company will, during the period when the Final Prospectus is required to be
delivered under the Securities Act and during which the Company is subject to
the reporting requirements of Section 13 or Section 15(d) of the Exchange Act,
timely file all Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and any other reports, statements, documents,
registrations, filings or submissions required to be filed by the Company with
the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act.
7
(g) The
Company will make generally available to its security holders as soon as
practicable, but not later than 90 days after the close of the period covered
thereby, an earnings statement (in form complying with the provisions of Rule
158 under the Securities Act) covering a twelve-month period beginning not later
than the first day of the Company’s fiscal quarter next following the “effective
date” (as defined in such Rule 158) of the Registration Statement.
(h) The
Company will cooperate with the Representatives and use its reasonable best
efforts to permit the Notes to be eligible for clearance and settlement through
DTC.
(i) The
Company agrees that, unless it has obtained the prior written consent of the
Representatives, and each Underwriter, severally and not jointly, agrees with
the Company that, unless it has obtained the prior written consent of the
Company, it has not made and will not make any offer relating to the Notes that
would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a “free writing prospectus” (as defined in Rule 405) required to be
filed by the Company with the Commission or retained by the Company under Rule
433, other than the information contained in the final term sheet prepared and
filed pursuant to Section 4(I)(c) hereto; provided that the prior written
consent of the parties hereto shall be deemed to have been given in respect of
the Free Writing Prospectuses included in Schedule III hereto. Any such free
writing prospectus consented to by the Representatives or the Company is
hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company
agrees that (x) it has treated and will treat, as the case may be, each
Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (y)
it has complied and will comply, as the case may be, with the requirements of
Rules 164 and 433 applicable to any Permitted Free Writing Prospectus, including
in respect of timely filing with the Commission, legending and record
keeping.
(II) Each
Underwriter, on behalf of itself and each of its affiliates that participates in
the initial distribution of the Notes, severally represents to and agrees with
the Company that it and each such affiliate:
(a) in
relation to each Member State of the European Economic Area which has
implemented the Prospectus Directive (each, a Relevant Member State), with
effect from and including the date on which the Prospectus Directive is
implemented in that Relevant Member State (the Relevant Implementation Date),
has not made and will not make an offer of Notes to the public in that Relevant
Member State prior to the publication of a prospectus in relation to the Notes
which has been approved by the competent authority in that Relevant Member State
or, where appropriate, approved in another Relevant Member State and notified to
the competent authority in that Relevant Member State, all in accordance with
the Prospectus Directive, except that it may, with effect from and including the
Relevant Implementation Date, make an offer of Notes to the public in that
Relevant Member State at any time,
8
(i)
to legal
entities which are authorized or regulated to operate in the financial markets
or, if not so authorized or regulated, whose corporate purpose is solely to
invest in securities;
(ii)
to any
legal entity which has two or more of (1) an average of at least 250 employees
during its last financial year; (2) a total balance sheet of more than
€43,000,000; and (3) an annual net turnover of more than €50,000,000, as shown
in its last annual or consolidated accounts;
(iii)
to fewer
than 100 natural or legal persons (other than qualified investors as defined in
the Prospectus Directive) subject to obtaining the prior consent of the
Representatives for any such offer; or
(iv)
in any
other circumstances which do not require the publication by the Company of a
prospectus pursuant to Article 3 of the Prospectus Directive.
For the
purposes of this provision, the expression an “offer of Notes to the public” in
relation to any Notes in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms of the offer
and the Notes to be offered so as to enable an investor to decide to purchase or
subscribe the Notes, as the same may be varied in that Member State by any
measure implementing the Prospectus Directive in that Member State, and the
expression “Prospectus Directive” means Directive 2003/71/EC and includes any
relevant implementing measure in each Relevant Member State;
(b) has only
communicated or caused to be communicated and will only communicate or cause to
be communicated an invitation or inducement to engage in investment activity
(within the meaning of section 21 of the United Kingdom Financial Services and
Markets Xxx 0000, or “FSMA”) to persons who
have professional experience in matters relating to investments falling within
Article 19(5) of the Financial Services and Markets Xxx 0000 (Financial
Promotion) Order 2005 or in circumstances in which section 21 of FSMA does not
apply to the Company; and has complied with, and will comply with all applicable
provisions of FSMA with respect to anything done by it in relation to the Notes
in, from or otherwise involving the United Kingdom; and
(c) will not
offer or sell any of the Notes directly or indirectly in Japan or to, or for the
benefit of any Japanese person or to others, for re-offering or re-sale directly
or indirectly in Japan or to any Japanese person, except in each case pursuant
to an exemption from the registration requirements of, and otherwise in
compliance with, the Securities and Exchange Law of Japan and any other
applicable laws and regulations of Japan. For purposes of this paragraph,
“Japanese person” means any person resident in Japan, including any corporation
or other entity organized under the laws of Japan.
(III)
Mitsubishi
UFJ Securities International plc, on behalf of itself and each of its affiliates
that participates in the initial distribution of the Notes, represents to and
agrees with the Company that, to the extent that it intends to effect any sales
of the Notes in the United States, it will do so through one or more U.S.
registered broker-dealers as permitted by Financial Industry Regulatory
Authority regulations.
9
5. Conditions to the
Obligations of the Underwriters. The obligations of the Underwriters to
purchase the Notes shall be subject to the accuracy of the representations and
warranties on the part of the Company contained herein at the date and time that
this Agreement is executed and delivered by the parties hereto, at the
Applicable Time, and at the Closing Date and to the accuracy of the statements
of the Company made in any certificates pursuant to the provisions hereof, to
the performance by the Company of its obligations hereunder and to the following
additional conditions:
(a) The Final
Prospectus, and any supplement thereto, have been filed in the manner and within
the time period required by Rule 424(b); the final term sheet contemplated by
Section 4(I)(c) hereto, and any other material required to be filed by the
Company pursuant to Rule 433(d) under the Securities Act, shall have been filed
with the Commission within the applicable time periods prescribed for such
filings by Rule 433; and no stop order suspending the effectiveness of the
Registration Statement or any notice objecting to its use shall have been issued
and no proceedings for that purpose shall have been instituted or
threatened.
(b) The
Company shall have furnished to the Underwriters the opinion of the Senior Vice
President — Law and Public Affairs and Corporate Secretary, the General Counsel
or an Assistant General Counsel of the Company, dated the Closing Date, to the
effect that:
(i) The
Company has been duly incorporated and is an existing corporation in good
standing under the laws of the Commonwealth of Virginia, with corporate power
and authority to own, lease and operate its properties and conduct its business
as described in the Disclosure Package and the Final Prospectus; and the Company
is duly qualified to do business as a foreign corporation in good standing in
all other jurisdictions in which it owns or leases substantial properties or in
which the conduct of its business requires such qualification except where the
failure to so qualify or be in good standing would not have a material adverse
effect on the Company and its subsidiaries, considered as one
enterprise;
(ii) Each
significant subsidiary as defined in Rule 405 of Regulation C of the Securities
Act (each a “Significant
Subsidiary”) of the Company has been duly incorporated or formed, as the
case may be, and is validly existing as a corporation or limited liability
company, as the case may be, in good standing under the laws of the jurisdiction
of its incorporation or formation, as the case may be, has organizational power
and authority to own, lease and operate its properties and conduct its business
as described in the Disclosure Package and the Final Prospectus; and, to the
best of such counsel’s knowledge, is duly qualified as a foreign corporation or
limited liability company, as the case may be, to transact business and is in
good standing in each jurisdiction in which such qualification is required,
except where the failure to so qualify or be in good standing would not have a
material adverse effect on the Company and its subsidiaries, considered as one
enterprise; all of the issued and outstanding capital stock or membership
interests, as the case may be, of each Significant Subsidiary has been duly
authorized and validly issued, is fully paid and nonassessable, and, except for
directors’ qualifying shares, if any, is owned, directly or indirectly, by the
Company free and clear of any mortgage, pledge, lien, encumbrance, claim or
equity, except as would not reasonably be expected to have a material adverse
effect on the Company and its subsidiaries, considered as one
enterprise;
10
(iii) This
Agreement and the Indenture have been duly authorized, executed and delivered by
the Company;
(iv) No
consent, approval, authorization or order of, or filing with, any governmental
agency or body or any court is required for the consummation of the transactions
contemplated herein, except for a filing of any Preliminary Prospectus or the
Final Prospectus under Rule 424(b) of the Securities Act and such as may be
required under state securities laws;
(v) The
execution, delivery and performance of this Agreement and the issuance and sale
of the Notes and compliance with the terms and provisions thereof will not
result in a material breach or violation of any of the terms and provisions of,
or constitute a default under, any statute, rule, regulation or order of any
governmental agency or body or any court having jurisdiction over the Company or
any Significant Subsidiary or any of their properties or, to the best of such
counsel’s knowledge, any agreement or instrument to which the Company or any of
its Significant Subsidiaries is a party or by which the Company or any
Significant Subsidiary is bound or to which any of the properties of the Company
or any Significant Subsidiary is subject, or the charter, bylaws or operating
agreement, as the case may be, of the Company or any Significant
Subsidiary.
(vi) The
Company has full power and authority to authorize, issue and sell the Notes as
contemplated by this Agreement, and the Notes have been duly authorized,
executed and delivered by the Company; and
(vii)
Each
document filed pursuant to the Exchange Act and incorporated by reference in the
Disclosure Package and the Final Prospectus complied when filed as to form in
all material respects with the Exchange Act and the rules and regulations
promulgated thereunder.
In
addition, such counsel shall state that he or she has, or persons under his or
her supervision have, participated in conferences with officers and other
representatives of the Company, representatives of Ernst & Young LLP,
independent auditors for the Company, the Representatives and Counsel for the
Underwriters, at which the contents of the Registration Statement and any
Preliminary Prospectus, the Disclosure Package or the Final Prospectus and any
amendment thereof or supplement thereto and related matters were discussed, and,
although such counsel has not undertaken to investigate or verify independently,
and does not assume any responsibility for, the accuracy, completeness or
fairness of the statements contained in the Registration Statement, the
Disclosure Package or any Preliminary Prospectus or the Final Prospectus or any
amendment thereof or supplement thereto, no facts have come to the attention of
such counsel that would lead such counsel to believe (A) that the Registration
Statement (other than the historical, pro forma, projected or other financial
statements, information and data and statistical information and data included
or incorporated by reference therein or omitted therefrom, and Form T-1, in each
case as to which no opinion need be given), at the Applicable Time, contained
any untrue statement of a material fact, or omitted to state a material fact
necessary in order to make the statements therein not misleading or (B) that (i)
the Disclosure Package, as of the Applicable Time, and (ii) the Final
Prospectus, as amended or supplemented as of its date or as of the Closing Date
(in each case, other than the historical, pro forma, projected or other
financial statements, information and data and statistical information and data
included or incorporated by reference therein or omitted therefrom, in each case
as to which no opinion need be given), includes or will include any untrue
statement of a material fact or omits or will omit to state a material fact
necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. Except as otherwise
set forth herein, all references in this Section 5(b) to the Final Prospectus
shall be deemed to include any amendment or supplement thereto at the Closing
Date.
11
(c) The
Company shall have furnished to the Underwriters the opinion of Cravath, Swaine
& Xxxxx LLP, counsel for the Company, dated the Closing Date, to the effect
that:
(i) Assuming
that the Indenture has been duly authorized, executed and delivered by the
Company, the Indenture has been duly qualified under the Trust Indenture Act of
1939 and constitutes a legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms (subject to
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
transfer and other similar laws affecting creditors’ rights generally from time
to time in effect and to general principles of equity, including, without
limitation, concepts of materiality, reasonableness, good faith and fair
dealing, regardless of whether considered in a proceeding in equity or at law);
and assuming that the Notes have been duly authorized, when the Notes are
executed and authenticated in accordance with the provisions of the Indenture
and delivered to and paid for by the Underwriters pursuant to this Agreement,
the Notes conform in all material respects to the description thereof contained
in the Disclosure Package, the Base Prospectus and the Final Prospectus and will
constitute legal, valid and binding obligations of the Company entitled to the
benefits of the Indenture and enforceable against the Company in accordance with
their terms (subject to applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent transfer and other similar laws affecting creditors’
rights generally from time to time in effect and to general principles of
equity, including, without limitation, concepts of materiality, reasonableness,
good faith and fair dealing, regardless of whether considered in a proceeding in
equity or at law);
12
(ii) This
Agreement has been duly authorized, executed and delivered by the
Company;
(iii) The
Registration Statement initially became effective under the Securities Act on
February 15, 2007; the Preliminary Prospectus was filed with the Commission
pursuant to Rule 424(b)(3), the Final Prospectus was filed with the Commission
pursuant to Rule 424(b)(5), and a term sheet was filed with the Commission
pursuant to Rule 433. Thereupon, assuming prior payment by the Company of the
pay-as-you-go registration fee for the offering of Notes, upon the filing of the
Base Prospectus and the Final Prospectus with the Commission, the offering of
the Notes as contemplated by the Base Prospectus and the Final Prospectus became
registered under the Securities Act; to such counsel’s knowledge, no stop order
suspending the effectiveness of the Registration Statement has been issued and
no proceedings for that purpose have been instituted or are pending or
contemplated under the Securities Act;
(iv) The
Company is not an “investment company” as such term is defined in the Investment
Company Act of 1940, as amended;
(v) The
statements made in the Disclosure Package, the Base Prospectus and the Final
Prospectus under the captions “Description of Debt Securities” and “Description
of Notes,” insofar as they purport to constitute summaries of the terms of the
Notes and the Indenture, and under the caption “Certain Tax Considerations,”
insofar as they purport to describe the material tax consequences of an
investment in the Notes, fairly summarize the matters therein
described;
In
addition, subject to such counsel’s customary qualifications about the scope of
its obligations in connection with its participation in the preparation of
documents, such counsel shall state that they have participated in conferences
with officers and other representatives of the Company, representatives of Ernst
& Young LLP, independent auditors for the Company, the Representatives and
Counsel for the Underwriters at which the contents of the Registration
Statement, Disclosure Package and the Final Prospectus and any amendment thereof
or supplement thereto and related matters were discussed, and, although such
counsel have not undertaken to investigate or verify independently, and do not
assume any responsibility for, the accuracy, completeness or fairness of the
statements contained in the Registration Statement, Disclosure Package and the
Final Prospectus or any amendment thereof or supplement thereto (other than to
the extent addressed in paragraph (c)(i) and paragraph (c)(v) in this Section
5), and did not participate in the preparation of the documents incorporated by
reference in the Registration Statement or any Preliminary Prospectus and the
Final Prospectus, (A) the Registration Statement, at the time it initially
became effective, appeared on its face to be appropriately responsive in all
material respects to the requirements of the Securities Act and the rules and
regulations promulgated thereunder (except that such counsel need not express
any view as to the financial statements and other information of a statistical,
accounting or financial nature included in the Registration Statement or the
Statement of Eligibility (Form T-1)); and (B) no facts have come to the
attention of such counsel that would lead such counsel to believe (i) that the
Registration Statement (other than the historical, pro forma, projected or other
financial statements, information and data and statistical information and data
included or incorporated by reference therein or omitted therefrom, and Form
T-1, in each case as to which no opinion need be given), at the Applicable Time,
contained any untrue statement of a material fact, or omitted to state a
material fact necessary in order to make the statements therein not misleading
or (ii) that (x) the Disclosure Package, as of the Applicable Time, or (y) the
Final Prospectus as amended or supplemented as of its date or as of the Closing
Date (in each case, other than the historical, pro forma, projected or other
financial statements, information and data and statistical information and data
included or incorporated by reference therein or omitted therefrom, in each case
as to which no opinion need be given) includes or will include any untrue
statement of a material fact or omits or will omit to state a material fact
necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading.
13
In
rendering such opinion, Cravath, Swaine & Xxxxx LLP may rely (A) as to
matters governed by Virginia law upon the opinion of the Senior Vice President —
Law and Public Affairs and Corporate Secretary, General Counsel or Assistant
General Counsel of the Company and (B) as to matters of fact, to the extent they
deem proper, on certificates of responsible officers of the Company and public
officials. Except as otherwise set forth herein, all references in this Section
5(c) to the Final Prospectus shall be deemed to include any amendment or
supplement thereto at the Closing Date.
(d) The
Representatives shall have received from Counsel for the Underwriters such
opinion or opinions, dated the Closing Date, with respect to the issuance and
sale of the Notes, the Registration Statement, the Disclosure Package and the
Final Prospectus (as amended or supplemented at the Closing Date) and other
related matters as they may require, and the Company shall have furnished to
such counsel such documents as they may reasonably request for the purpose of
enabling them to pass upon such matters. In rendering such opinion, Counsel for
the Underwriters may rely as to all matters governed by Virginia law on the
opinion of the Senior Vice President — Law and Public Affairs and Corporate
Secretary, General Counsel or Assistant General Counsel of the Company, referred
to above.
(e) The
Company shall have furnished to the Representatives a certificate of the
Company, signed by the Chairman of the Board, President and Chief Executive
Officer, any Vice President or the Assistant Vice President — Capital Markets
and another person who is the principal financial or accounting officer of the
Company, or, in their absence, other proper officers of the Company satisfactory
to the Representatives, dated the Closing Date, to the effect that the signers
of such certificate have examined the Registration Statement, the Disclosure
Package, the Final Prospectus, any amendment or supplement thereto and this
Agreement and that, to the best of their knowledge after reasonable
investigation:
(i) the
representations and warranties of the Company in this Agreement are true and
correct in all material respects on and as of the Closing Date with the same
effect as if made on and as of such date, and the Company has complied with all
the agreements and satisfied all the conditions on its part to be performed or
satisfied hereunder at or prior to the Closing Date; and
14
(ii) since the
date of the most recent financial statements incorporated by reference in the
Disclosure Package and the Final Prospectus, there has been no material adverse
change in the condition (financial or other), earnings, business or properties
of the Company and its subsidiaries considered as one enterprise, whether or not
arising from transactions in the ordinary course of business, except as set
forth in or contemplated by the Disclosure Package and the Final Prospectus
(exclusive of any amendment or supplement thereto after the date hereof) or as
described in such certificate.
(f) At the
Applicable Time and at the Closing Date, Ernst & Young LLP shall have
furnished to the Representatives letters, dated respectively as of the
Applicable Time and as of the Closing Date, in form and substance satisfactory
to the Representatives, confirming that they are independent accountants within
the meaning of the Securities Act and the Exchange Act and the respective
applicable rules and regulations adopted by the Commission thereunder and
containing statements and information of the type ordinarily included in
accountants’ “comfort letters” to underwriters with respect to the financial
statements and certain financial information contained in the Registration
Statement, Preliminary Prospectus and Final Prospectus.
(g) Subsequent
to the Applicable Time or, if earlier, the dates as of which information is
given in the Registration Statement (exclusive of any amendment thereof) and the
Final Prospectus (exclusive of any supplement thereto), there shall not have
been (i) any change or decrease specified in the letters referred to in
paragraph (f) of this Section 5 or (ii) any change, or any development involving
a prospective change, in or affecting the business or properties of the Company
and its subsidiaries, the effect of which, in any case referred to in clause (i)
or (ii) above, is, in the reasonable judgment of the Representatives, so
material and adverse as to make it impractical or inadvisable to market the
Notes as contemplated by the Disclosure Package and the Final Prospectus
(exclusive of any amendment or supplement thereof or thereto after the date
hereof).
(h) Subsequent
to the Applicable Time, there shall not have been any decrease in the rating of
any of the Company’s debt securities by Xxxxx’x Investors Service, Inc. or
Standard & Poor’s Ratings Group or any notice given of any intended or
potential decrease in any such rating or of a possible change in any such rating
that does not indicate the direction of the possible change.
(i) Prior to
the Closing Date, the Company shall furnish to the Representatives such
conformed copies of such opinions, certificates, letters and documents as the
Representatives may reasonably request.
If any of
the conditions specified in this Section 5 shall not have been fulfilled in all
material respects when and as provided in this Agreement, or if any of the
opinions and certificates mentioned above or elsewhere in this Agreement shall
not be in all material respects reasonably satisfactory in form and substance to
the Representatives and Counsel for the Underwriters, this Agreement and all
obligations of the Underwriters hereunder with respect to the Notes may be
canceled at, or at any time prior to, the Closing Date by the Representatives.
Notice of such cancellation shall be given to the Company in writing or by
telephone or telefax confirmed in writing.
15
The
documents required to be delivered by this Section 5 will be delivered at the
office of Counsel for the Underwriters, at 000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, Xxx
Xxxx 00000, on the Closing Date.
6. Reimbursement of
Expenses. If the sale of the Notes provided for herein is not consummated
because of cancellation by the Representatives pursuant to Section 5 hereof,
because of any termination pursuant to Section 9 hereof or because of any
refusal, inability or failure on the part of the Company to perform any material
agreement herein or comply with any material provision hereof other than by
reason of a default by any of the Underwriters in payment for the Notes on the
Closing Date, the Company will reimburse the Underwriters severally upon demand
for all reasonable out-of-pocket expenses (including reasonable fees and
disbursements of Counsel for the Underwriters) that shall have been incurred by
them in connection with the proposed purchase and sale of the
Notes.
7. Indemnification and
Contribution. (a) The Company agrees to indemnify and hold harmless each
Underwriter, the directors, officers, employees, affiliates and agents of each
Underwriter and each person who controls any Underwriter within the meaning of
either Section 15 of the Securities Act or Section 20 of the Exchange Act
against any and all losses, claims, damages or liabilities, joint or several, to
which they or any of them may become subject under the Securities Act, the
Exchange Act or other federal or state statutory law or regulation, at common
law or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon any untrue statement
or alleged untrue statement of a material fact contained in the Registration
Statement, or in the Base Prospectus, any Preliminary Prospectus or any other
preliminary prospectus supplement relating to the Notes, the Final Prospectus,
any Issuer Free Writing Prospectus or the information contained in the final
term sheet required to be prepared and filed pursuant to Section 4(I)(c) hereto,
or in any amendment thereof or supplement thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading, and agrees to
reimburse each such indemnified party for any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss,
claim, damage, liability or action as such expenses are incurred; provided, however, that the Company will not be liable in
any such case to the extent that any such loss, claim, damage or liability
arises out of or is based upon any such untrue statement or alleged untrue
statement or omission or alleged omission made therein in reliance upon and in
conformity with written information furnished to the Company by or on behalf of
any Underwriters through the Representatives specifically for inclusion therein.
This indemnity agreement will be in addition to any liability the Company may
otherwise have.
(b) Each
Underwriter severally and not jointly agrees to indemnify and hold harmless the
Company, its directors, its officers, and each person who controls the Company
within the meaning of either Section 15 of the Securities Act or Section 20 of
the Exchange Act, to the same extent as the foregoing indemnity from the Company
to each Underwriter, but only with reference to information relating to such
Underwriter furnished in writing to the Company by or on behalf of such
Underwriter through the Representatives specifically for inclusion in the
documents referred to in the foregoing indemnity. This indemnity agreement will
be in addition to any liability which any Underwriter may otherwise have. The
Company and each Underwriter acknowledge that the statements set forth in the
fourth paragraph, sixth paragraph, twelfth paragraph, thirteenth paragraph and
fourteenth paragraph of text under the heading “Underwriting” in the Preliminary
Prospectus and the fourth paragraph, sixth paragraph, thirteenth paragraph,
fourteenth paragraph and fifteenth paragraph of text under the heading
“Underwriting” in the Final Prospectus constitute the only information furnished
in writing by or on behalf of the Underwriters for inclusion in the Preliminary
Prospectus or the Final Prospectus (or in any amendment or supplement thereto).
The Company and Mitsubishi UFJ Securities International plc acknowledge that the
statements set forth in the seventh paragraph of text under the heading
“Underwriting” in the Final Prospectus constitute information furnished in
writing by or on behalf of Mitsubishi UFJ Securities International plc for
inclusion in the Preliminary Prospectus or the Final Prospectus (or in any
amendment or supplement thereto).
16
(c) Promptly
after receipt by an indemnified party under this Section 7 of notice of the
commencement of any action, such indemnified party will, if a claim in respect
thereof is to be made against the indemnifying party under this Section 7,
notify the indemnifying party in writing of the commencement thereof; but the
failure so to notify the indemnifying party (i) will not relieve it from
liability under paragraph (a) or (b) above unless and to the extent it did not
otherwise learn of such action and such failure results in the forfeiture by the
indemnifying party of substantial rights and defenses and (ii) will not, in any
event, relieve the indemnifying party from any obligations to any indemnified
party other than the indemnification obligation provided in paragraph (a) or (b)
above. The indemnifying party shall be entitled to appoint counsel of the
indemnifying party’s choice at the indemnifying party’s expense to represent the
indemnified party in any action for which indemnification is sought (in which
case the indemnifying party shall not thereafter be responsible for the fees and
expenses of any separate counsel retained by the indemnified party or parties
except as set forth below); provided, however, that such counsel shall be reasonably
satisfactory to the indemnified party. Notwithstanding the indemnifying party’s
election to appoint counsel to represent the indemnified party in an action, the
indemnified party shall have the right to employ separate counsel (including
local counsel); however, the indemnifying party shall bear the reasonable fees,
costs and expenses of such separate counsel only if (i) the use of counsel
chosen by the indemnifying party to represent the indemnified party would
present such counsel with a conflict of interest, (ii) the actual or potential
defendants in, or targets of, any such action include both the indemnified party
and the indemnifying party and the indemnified party shall have reasonably
concluded upon advice of counsel that there may be legal defenses available to
it and/or other indemnified parties which are different from or additional to
those available to the indemnifying party, (iii) the indemnifying party shall
not have employed counsel reasonably satisfactory to the indemnified party to
represent the indemnified party within a reasonable time after notice of the
institution of such action or (iv) the indemnifying party shall authorize the
indemnified party to employ separate counsel at the expense of the indemnifying
party. An indemnifying party will not, without the prior written consent of the
indemnified parties, settle or compromise or consent to the entry of any
judgment with respect to any pending or threatened claim, action, suit or
proceeding in respect of which indemnification or contribution may be sought
hereunder (whether or not the indemnified parties are actual or potential
parties to such claim or action) unless such settlement, compromise or consent
(i) includes an unconditional release of each indemnified party from all
liability arising out of such claim, action, suit or proceeding and (ii) does
not include a statement as to, or an admission of, fault, culpability or a
failure to act, by or on behalf of any indemnified party. An indemnifying party
shall not be liable under this Section 7 to any indemnified party regarding any
settlement or compromise or consent to the entry of any judgment with respect to
any pending or threatened claim, action, suit or proceeding in respect of which
indemnification or contribution may be sought hereunder (whether or not the
indemnified parties are actual or potential parties to such claim or action)
unless such settlement, compromise, or consent is consented to by such
indemnifying party, which consent shall not be unreasonably
withheld.
17
(d) If the
indemnity provided in paragraph (a) or (b) of this Section 7 is unavailable to
or insufficient to hold harmless an indemnified party for any reason, the
Company and the Underwriters agree to contribute to the aggregate losses,
claims, damages and liabilities (including legal or other expenses reasonably
incurred in connection with investigating or defending same) (collectively
“Losses”) to
which the Company and one or more of the Underwriters may be subject in such
proportion as is appropriate to reflect the relative benefits received by the
Company and by the Underwriters from the offering of the Notes. If the
allocation provided by the immediately preceding sentence is unavailable for any
reason, the Company and the Underwriters shall contribute in such proportion as
is appropriate to reflect not only such relative benefits but also the relative
fault of the Company and of the Underwriters in connection with the statements
or omissions which resulted in such Losses as well as any other relevant
equitable considerations. Benefits received by the Company shall be deemed to be
equal to the total net proceeds from the offering (before deducting expenses),
and benefits received by the Underwriters shall be deemed to be equal to the
total purchase discounts and commissions received by the Underwriters from the
Company in connection with the purchase of the Notes hereunder, in each case as
set forth on the cover page of the Final Prospectus. Relative fault shall be
determined by reference to whether any alleged untrue statement or omission
relates to information provided by the Company or the Underwriters, the intent
of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such untrue statement or omission. The Company
and the Underwriters agree that it would not be just and equitable if
contribution were determined by pro rata allocation or any other method of
allocation which does not take account of the equitable considerations referred
to above. Notwithstanding the provisions of this paragraph (d), no person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Underwriters’ obligations to
contribute as provided in this Section 7(d) are several in proportion to their
respective purchase obligations and not joint. For purposes of this Section 7,
each person who controls an Underwriter within the meaning of either Section 15
of the Securities Act or Section 20 of the Exchange Act and each director,
officer, employee and agent of an Underwriter shall have the same rights to
contribution as such Underwriter, and each person who controls the Company
within the meaning of either Section 15 of the Securities Act or Section 20 of
the Exchange Act and each officer and director of the Company shall have the
same rights to contribution as the Company, subject in each case to the
applicable terms and conditions of this paragraph (d). Notwithstanding the
provisions of this paragraph (d), in no case shall any Underwriter (except as
may be provided in any agreement among the Underwriters relating to the offering
of the Notes) be responsible for any amount in excess of the purchase discount
or commission applicable to the Notes purchased by such Underwriter hereunder,
in each case as set forth on the cover page of the Final
Prospectus.
18
8. Default by an
Underwriter. If any one or more Underwriters shall fail to purchase and
pay for any of the Notes agreed to be purchased by such Underwriter hereunder
and such failure to purchase shall constitute a default in the performance of
its or their obligations under this Agreement, the remaining Underwriters shall
be obligated severally to take up and pay for (in the respective proportions
which the principal amount of Notes set forth opposite their names in Schedule
II hereto bears to the aggregate principal amount of Notes set forth opposite
the names of all the remaining Underwriters) the Notes which the defaulting
Underwriter or Underwriters agreed but failed to purchase; provided, however, that if the aggregate
principal amount of Notes which the defaulting Underwriter or Underwriters
agreed but failed to purchase shall exceed 10% of the aggregate principal amount
of Notes set forth in Schedule II hereto, the remaining Underwriters shall have
the right to purchase all, but shall not be under any obligation to purchase
any, of the Notes, and if such non-defaulting Underwriters do not purchase all
the Notes within 36 hours of such default, this Agreement will terminate without
liability to any non-defaulting Underwriter or the Company except as otherwise
provided in Section 10. In the event of a default by any Underwriter as set
forth in this Section 8, the Closing Date shall be postponed for such period,
not exceeding seven days, as the Representatives shall determine in order that
the required changes in the Final Prospectus or in any other documents or
arrangements may be effected. Nothing contained in this Agreement shall relieve
any defaulting Underwriter of its liability, if any, to the Company or to any
non-defaulting Underwriter for damages occasioned by its default
hereunder.
9. Termination. This
Agreement shall be subject to termination in the absolute discretion of the
Representatives, by notice given to the Company prior to delivery of and payment
for the applicable Notes, if prior to such time (i) there shall have occurred
any change, or any development involving a prospective change, in or affecting
particularly the business or properties of the Company or its subsidiaries
which, in the judgment of the Representatives, materially impairs the investment
quality of the Notes, (ii) any downgrading in the rating of any debt securities
of the Company by any “nationally recognized statistical rating organization”
(as defined for purposes of Rule 436(g) under the Securities Act), or any public
announcement that any such organization has under surveillance or review its
rating of any debt securities of the Company (other than an announcement with
positive implications of a possible upgrading, and no implication of a possible
downgrading, of such rating), (iii) trading in any of the Company’s securities
shall have been suspended by the Commission or the New York Stock Exchange or
trading in securities generally on the New York Stock Exchange shall have been
suspended or materially limited or minimum prices shall have been established on
such exchange, (iv) a banking moratorium shall have been declared either by
federal or New York State authorities or (v) there shall have occurred any
outbreak or escalation of hostilities, declaration by the United States of a
national emergency or war or other calamity or crisis the effect of which on
financial markets is such as to make it, in the reasonable judgment of the
Representatives, impracticable or inadvisable to proceed with the offering or
delivery of the Notes as contemplated by any Preliminary Prospectus or the Final
Prospectus (exclusive of any amendment or supplement thereof or thereto after
the date hereof).
19
10. Representations and
Indemnities to Survive. The respective agreements, representations,
warranties, indemnities and other statements of the Company or its officers and
of the Underwriters set forth in or made pursuant to this Agreement will remain
in full force and effect, regardless of any investigation made by or on behalf
of the Underwriters or the Company or any of the officers, directors or
controlling persons referred to in Section 7 hereof, and will survive delivery
of and payment for the Notes. The provisions of Sections 6 and 7 hereof shall
survive the termination or cancellation of this Agreement.
11. Fees, Expenses. The
Company covenants and agrees with the Representatives that the Company will pay
or cause to be paid the following: (i) the fees, disbursements and expenses of
the Company’s counsel and accountants in connection with the issue of the Notes
and all other expenses in connection with the preparation and printing of the
Final Prospectus and any amendments and supplements thereto and the mailing and
delivering of copies thereof to the Underwriters; (ii) the cost of printing or
other production of all documents relating to the offering, purchase, sale and
delivery of the Notes as provided in Section 4(I)(a); (iii) any fees charged by
securities rating services for rating the Notes; (iv) the cost of preparing the
Notes; (v) the fees and expenses of the Trustee and any agent of the Trustee and
the fees and disbursements of counsel for the Trustee in connection with the
Indenture and the Notes; (vi) any fees charged by DTC; (vii) all expenses in
connection with the qualification of the Notes for offering and sale under state
and Canadian securities laws, including the fees and disbursements of Counsel
for the Underwriters in connection with such qualification and in connection
with Blue Sky and Legal Investment Survey and Canadian offering documents; and
(viii) all other costs and expenses incident to the performance of its
obligations hereunder which are not otherwise specifically provided for in this
Section 11. It is understood, however, that except as provided in Sections 6 and
11 hereof, the Underwriters will pay all of their own costs and expenses,
including the fees, disbursements and expenses of their counsel and any
marketing expenses connected with any offers they may make.
12. Notices. All
communications hereunder will be in writing and effective only on receipt, and,
if sent to the Representatives, will be mailed, delivered or telefaxed and
confirmed to them, care of (i) Credit Suisse Securities (USA) LLC, Eleven
Madison Avenue, New York, N.Y. 10010-3629, attention: Xxxx Xxxxxxxxx, phone:
(000) 000-0000, facsimile: (000) 000-0000; and (ii) X.X. Xxxxxx Securities Inc.,
000 Xxxx Xxxxxx, Xxx Xxxx, X.X. 00000, attention: High Grade Syndicate Desk,
phone: (000) 000-0000, facsimile: (000) 000-0000; and (iii) UBS Securities LLC,
000 Xxxxxxxxxx Xxxxxxxxx, Xxxxxxxx, XX 00000, attention: Fixed Income Syndicate,
facsimile: (000) 000 0000; or, if sent to the Company, will be mailed, delivered
or telefaxed and confirmed to it at CSX Corporation, 000 Xxxxx Xxxxxx, 0xx Xxxxx,
Xxxxxxxxxxxx, Xxxxxxx 00000, attention: Xxxxx X. Xxxxx, Assistant Vice President
— Capital Markets, telefax number (000) 000-0000.
13. Successors. This
Agreement will inure to the benefit of and be binding upon the parties hereto
and their respective successors and the officers and directors and controlling
persons referred to in Section 7 hereof, and no other person will have any right
or obligation hereunder.
14. Applicable Law. This
Agreement will be governed by and construed in accordance with the laws of the
State of New York.
20
15. No Fiduciary Duty.
The Company hereby acknowledges that (a) the purchase and sale of the Notes
pursuant to this Agreement is an arm’s-length commercial transaction between the
Company, on the one hand, and the Underwriters and any affiliate through which
it may be acting, on the other, (b) the Underwriters are acting as principal and
not as an agent or fiduciary of the Company and (c) the Company’s engagement of
the Underwriters in connection with the offering and the process leading up to
the offering is as independent contractors and not in any other capacity.
Furthermore, the Company agrees that it is solely responsible for making its own
judgments in connection with the offering (irrespective of whether any of the
Underwriters has advised or is currently advising the Company on related or
other matters). The Company agrees that it will not claim that the Underwriters
have rendered advisory services of any nature or respect, or owe an agency,
fiduciary or similar duty to the Company, in connection with such transaction or
the process leading thereto.
16. Counterparts. This
Agreement may be executed in one or more counterparts, each of which will be
deemed to be an original, but all such counterparts will together constitute one
and the same instrument.
17. Headings. The section
headings are for convenience only and shall not affect the construction
hereof.
18. Definitions. The
terms which follow, when used in this Agreement, shall have the meanings
indicated.
“Applicable
Time” shall mean 4:00 PM (Eastern Time) on January 14, 2009 or such other time
as agreed by the Company and the Representatives.
“Base
Prospectus” shall mean the base prospectus referred to in Section 1(a) above
contained in the Registration Statement at the Applicable Time.
“Business
Day” shall mean each Monday, Tuesday, Wednesday, Thursday and Friday that is not
a day on which banking institutions in The City of New York, New York are
authorized or obligated by law, executive order or regulation to
close.
“Disclosure
Package” shall mean (i) the Preliminary Prospectus most recently distributed
generally to investors prior to the Applicable Time, (ii) the Issuer Free
Writing Prospectuses, if any, identified in Schedule III hereto, (iii) the final
term sheet prepared and filed pursuant to Section 4(I)(c) hereto, identified in
Schedule I hereto, if any, and (iv) any other Free Writing Prospectus that the
parties hereto shall hereafter expressly agree in writing to treat as part of
the Disclosure Package.
“Effective
Date” shall mean each date and time that the Registration Statement and any
post-effective amendment or amendments thereto became or become effective, and
each deemed effective date with respect to the Underwriters pursuant to Rule
430B(f)(2) under the Securities Act.
“Final
Prospectus” shall mean the prospectus supplement relating to the Notes that was
first filed pursuant to Rule 424(b) after the Applicable Time, together with the
Base Prospectus.
21
“Free
Writing Prospectus” shall mean a free writing prospectus, as defined in Rule
405.
“Issuer
Free Writing Prospectus” shall mean an issuer free writing prospectus, as
defined in Rule 433.
“Preliminary
Prospectus” shall mean any preliminary prospectus supplement to the Base
Prospectus referred to in Section 1(a) above which is used prior to the filing
of the Final Prospectus, together with the Base Prospectus.
“Registration
Statement” shall mean the registration statement referred to in Section 1(a)
above, as amended by Post-Effective Amendment No. 1 thereto, including exhibits
and financial statements and any prospectus supplement relating to the Notes
that is filed with the Commission pursuant to Rule 424(b) and deemed part of
such registration statement pursuant to Rule 430B, as amended on each Effective
Date and, in the event any post-effective amendment thereto becomes effective
prior to the Closing Date, shall also mean such registration statement as so
amended.
“Rule
158”, “Rule 163”, “Rule 164”, “Rule 172”, “Rule 405”, “Rule 415”, “Rule 424”,
“Rule 430B”, and “Rule 433” refer to such rules under the Securities
Act.
22
If the
foregoing is in accordance with your understanding of our agreement, please sign
and return to us the enclosed duplicate hereof, whereupon this Agreement and
your acceptance shall represent a binding agreement between the Company and the
Underwriters.
Very
truly yours,
CSX CORPORATION
|
|||
|
By:
|
/s/ Xxxxx X. Xxxx | |
Name: Xxxxx X. Xxxx | |||
Title: Vice President - Tax and Treasurer |
The foregoing Agreement is hereby confirmed and accepted as of the date first above written. | ||
CREDIT SUISSE SECURITIES (USA) LLC | ||
By:
|
/s/ Xxxx Xxxxxxxxx | |
Name: Xxxx Xxxxxxxxx | ||
Title: Managing Director |
X.X. XXXXXX SECURITIES INC. | ||
By:
|
/s/ Xxxxxxx X. Xxxxxxxx | |
Name: Xxxxxxx X. Xxxxxxxx | ||
Title: Vice President |
UBS SECURITIES LLC
|
||
By:
|
/s/ Xxxxxxxxx Xxxxxxx | |
Name: Xxxxxxxxx Xxxxxxx | ||
Title:
Managing Director
UBS Investment
Bank
|
By:
|
/s/ Xxxxxxxxxxx Xxxxxxxx | |
Name: Xxxxxxxxxxx Xxxxxxxx | ||
Title:
Associate Director
Debt Capital Markets
UBS Securities
LLC
|
For themselves and the other Underwriters named in
Schedule II to the foregoing Agreement
|
CSX
Corporation -- Underwriting Agreement Signature Page
SCHEDULE
I
PRICING
TERM SHEET
7.375%
Notes due 2019
Issuer:
|
CSX
Corporation
|
Security:
|
7.375%
Notes due 2019
|
Size:
|
$500,000,000
|
Maturity
Date:
|
February
1, 2019
|
Coupon:
|
7.375%
|
Interest
Payment Dates:
|
February
1st
and August 1st,
commencing August 1st,
2009
|
Price
to Public:
|
99.361%
|
Benchmark
Treasury:
|
3.750%
due November 15, 2018
|
Benchmark
Treasury Yield:
|
2.216%
|
Spread
to Benchmark Treasury:
|
+525
by
|
Yield:
|
7.466%
|
Make-Whole
Call:
|
T
+50 by
|
Expected
Settlement Date:
|
January
20, 2009
|
CUSIP:
|
126408
GQO
|
Anticipated
Ratings:
|
Baa3
(Stable) by Xxxxx’x Investors Service, Inc.
BBB-
(Neg.) by Standard & Poor’s Rating Services
BBB-
(Stable) by Fitch Ratings Ltd.
|
Joint
Book-Running Managers:
|
Credit
Suisse Securities (USA) LLC
X.X.
Xxxxxx Securities Inc.
UBS
Securities LLC
|
Senior
Co-Managers:
|
Barclays
Capital Inc.
Citigroup
Global Markets Inc.
Deutsche
Bank Securities Inc.
Xxxxxx
Xxxxxxx & Co. Incorporated
|
Co-Managers:
|
Mitsubishi
UFJ Securities International plc
Mizuho
Securities USA Inc.
Scotia
Capital (USA)
Inc.
|
Note:
A securities rating is not a recommendation to buy, sell or hold securities and
may be subject to revision or withdrawal at any time.
The
issuer has filed a registration statement (including a prospectus) with the SEC
for the offering to which this communication relates. Before you invest, you
should read the prospectus in that registration statement and other documents
the issuer has filed with the SEC for more complete information about the issuer
and this offering.
You
may get these documents for free by visiting XXXXX on the SEC Web site at xxx.xxx.xxx. Alternatively,
the issuer, any underwriter or any dealer participating in the offering will
arrange to send you the prospectus if you request it by calling Credit Suisse
Securities (USA) LLC toll free at 1 (800) 221-1037,
Sch.
I-1
X.X.
Xxxxxx Securities Inc. at 0-000-000-0000 or UBS Securities LLC toll free at 0
(000) 000-0000 xxx 0003884.
Sch.
I-2
SCHEDULE
II
$500,000,000
7.375% Notes Due 2019
Principal
Amount of
Notes
to be
|
|
Underwriters
|
Purchased
|
Credit
Suisse Securities (USA) LLC
|
$140,050,000
|
X.X.
Xxxxxx Securities Inc.
|
140,050,000
|
UBS
Securities LLC
|
140,050,000
|
Barclays
Capital Inc.
|
15,050,000
|
Citigroup
Global Markets Inc.
|
15,050,000
|
Deutsche
Bank Securities Inc.
|
15,050,000
|
Xxxxxx
Xxxxxxx & Co. Incorporated
|
15,050,000
|
Mitsubishi
UFJ Securities International plc
|
6,550,000
|
Mizuho
Securities USA Inc.
|
6,550,000
|
Scotia
Capital (USA) Inc.
|
6,550,000
|
Total
|
$500,000,000
|
Sch.
II-1
SCHEDULE
III
Schedule
of Free Writing Prospectuses included in the Disclosure Package
Pricing
Term Sheet
Sch.
III-1